A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
This research study is investigating a new medication called VENT-03 for adult patients diagnosed with cutaneous lupus erythematosus (CLE), a condition that primarily affects the skin, and who might also have systemic lupus erythematosus (SLE), which can affect various parts of the body. The main goals are to determine if VENT-03 can effectively reduce the symptoms and severity of CLE and to understand its safety profile. Participants will receive either VENT-03 or a placebo (a dummy treatment) for a short period, followed by everyone taking VENT-03. Regular clinic visits will be part of the study to monitor health and treatment effects. This study aims to find better treatment options for people living with these lupus conditions.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This clinical trial is designed to investigate a new medication, VENT-03, for individuals living with cutaneous lupus erythematosus (CLE), a type of lupus that mainly affects the skin, causing rashes and sores. Some participants might also have systemic lupus erythematosus (SLE), a more widespread form of lupus that can impact different organs and body systems. The research team wants to find out if VENT-03 can help improve the symptoms of CLE and reduce its severity.
Another important aim of this study is to gather information about the safety of VENT-03. Like all new medicines, it's crucial to understand any potential side effects it might have. Researchers will also be looking at how the body processes VENT-03. To do this, they will compare VENT-03 to a placebo, which looks exactly like the study medicine but contains no active drug. This comparison helps them determine if any changes observed are truly due to VENT-03 rather than other factors.
Ultimately, this study hopes to provide valuable insights into whether VENT-03 could become a new and effective treatment option for people with CLE, with or without SLE. Finding new and better ways to manage these conditions is important for improving the quality of life for those affected.
النقاط الرئيسية
- This study is for adults with a skin condition called cutaneous lupus (CLE), possibly with systemic lupus (SLE).
- It's testing a new medicine, VENT-03, to see if it helps reduce lupus skin symptoms and is safe.
- Participation involves taking either VENT-03 or a placebo first, then all participants take VENT-03 for a total of 12 weeks.
- Regular clinic visits (about once a month) are needed for check-ups and tests.
- It's a chance to access a new potential treatment and receive close medical monitoring.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
To be considered for this study, you must be an adult aged between 18 and 80 years old. You need to have active cutaneous lupus (CLE) with certain skin symptoms, such as specific types of rashes or sores. If you also have systemic lupus (SLE), you'll need to have had a positive blood test for specific antibodies and meet certain diagnostic criteria, while also being on stable treatment for your SLE.
There are also some reasons why you might not be able to join. For example, if you have certain infections, significant liver problems, or have had drug-induced lupus (rather than the more common type). You also wouldn't be able to participate if you have other inflammatory skin or joint conditions unrelated to lupus, or certain other health issues like active severe neurological lupus or cancer within a recent period (with some exceptions). The study also has rules around recent use of strong steroid medications or hospital stays for severe lupus flares.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك بين 18 و 80 سنة؟
- Do you have active cutaneous lupus (a skin form of lupus)?
- If you also have systemic lupus (SLE), are you currently on stable treatment for it?
- Do you have good overall health, without certain severe infections, serious liver disease, or active cancer?
- Have you avoided recent hospital stays for severe lupus flares or high-dose steroids for unrelated conditions?
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you'll first be given either the study medicine, VENT-03, or a placebo (a dummy pill) for 4 weeks. After this initial period, everyone in the study will then switch to taking VENT-03 for another 8 weeks. So, the total time you'll be taking the study medication or placebo is 12 weeks.
Throughout the study, you'll need to visit the clinic about once a month. These visits are important for the research team to carry out check-ups, conduct various tests (like blood tests), and monitor how you're responding to the treatment and if you're experiencing any side effects. These regular check-ups help ensure your safety and collect all the necessary information for the study.
المخاطر والفوائد المحتملة
المواقع (27)
- Investigative Siteالرمز البريدي المؤكدبيفرلي هيلز، الولايات المتحدة· التوظيف
- Investigative Siteالرمز البريدي المؤكدكليرووتر، الولايات المتحدة· التوظيف
- Investigative Siteالرمز البريدي المؤكدDeBary, United States· التوظيف
- Investigative Siteالرمز البريدي المؤكدتامبا، الولايات المتحدة· التوظيف
- Investigative Siteالرمز البريدي المؤكدSaint Joseph, United States· التوظيف
- Investigative Siteالرمز البريدي المؤكدFairport, United States· التوظيف
- Investigative Siteالرمز البريدي المؤكدممفيس، الولايات المتحدة· التوظيف
- Investigative Siteالرمز البريدي المؤكدAllen, United States· التوظيف
- Investigative Siteالرمز البريدي المؤكدأرلينغتون، الولايات المتحدة· التوظيف
- Investigative Siteالرمز البريدي المؤكدColleyville, United States· التوظيف
- Investigative Siteالرمز البريدي المؤكدHaskovo, Bulgaria· التوظيف
- Investigative Siteالرمز البريدي المؤكدPlovdiv, Bulgaria· التوظيف
أسئلة شائعة
What is cutaneous lupus (CLE)?
Cutaneous lupus is a type of lupus that mainly affects the skin, causing rashes, sores, and sometimes scarring.
What is systemic lupus (SLE)?
Systemic lupus is a more widespread form of lupus that can affect different organs and parts of your body, not just the skin.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' treatment that looks like the real medicine but doesn't contain any active drug. It helps researchers compare the effects.
ما هي المدة التي سأكون مشاركًا فيها في الدراسة؟
You'll be taking the study medicine or placebo for a total of 12 weeks. This includes an initial 4 weeks on either VENT-03 or placebo, followed by 8 weeks where everyone takes VENT-03.
Will I know if I'm receiving VENT-03 or the placebo?
No, initially neither you nor your doctor will know if you're receiving VENT-03 or the placebo. This is to ensure the study results are as fair and unbiased as possible. After 4 weeks, everyone will receive VENT-03.
كيفية معرفة المزيد
Krista Miller
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.